Search
Research
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaWe found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Research
Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patientsAll children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.
Research
Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemiaConnective tissue growth factor (CTGF/CCN2) has been shown previously to be aberrantly expressed in a high proportion of paediatric precursor B cell acute...
Research
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemiaBiological changes associated with T-ALL relapse and resistance are stochastic and highly individual
Research
Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemiaPre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms.
Research
Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemiaWe identified consistent hypomethylation of the CTGF locus in primary pre-B ALL specimens regardless of CTGF expression.
Research
Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemiaDrug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children.
Research
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolThe outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.